United Therapeutics (UTHR) EBITDA Margin Growth (3y) (2012 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) EBITDA Margin Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.35 Bn | 624.59 Bn | 17.26 Bn | 120.00 |
| 2 | AbbVie | 440.82 Bn | 434.25 Bn | 12.70 Bn | 531.00 |
| 3 | Merck | 364.35 Bn | 357.21 Bn | 12.21 Bn | 3,082.00 |
| 4 | Novartis Ag | 266.35 Bn | 258.66 Bn | 11.24 Bn | 842.00 |
| 5 | Pfizer | 158.92 Bn | 147.22 Bn | 10.94 Bn | 214.00 |
| 6 | Sanofi | 52.51 Bn | 45.13 Bn | 10.79 Bn | -963.00 |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | - |
| 8 | Incyte | 25.30 Bn | 20.76 Bn | 1.57 Bn | 2,139.00 |
| 9 | United Therapeutics | 21.40 Bn | 18.73 Bn | 683.80 Mn | -1,031.00 |
| 10 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | -46.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,031.00 |
| Mar 31, 2026 | -1,442.00 |
| Dec 31, 2025 | 941.00 |
| Sep 30, 2025 | -1,232.00 |
| Jun 30, 2025 | 242.00 |
| Mar 31, 2025 | -1,416.00 |
| Dec 31, 2024 | 771.00 |
| Sep 30, 2024 | -561.00 |
| Jun 30, 2024 | -502.00 |
| Mar 31, 2024 | 6,967.00 |
| Dec 31, 2023 | 2,535.00 |
| Sep 30, 2023 | -451.00 |
| Jun 30, 2023 | 1,373.00 |
| Mar 31, 2023 | 932.00 |
| Dec 31, 2022 | 1,532.00 |
| Sep 30, 2022 | 1,523.00 |
| Jun 30, 2022 | -1,604.00 |
| Mar 31, 2022 | 24,324.00 |
| Dec 31, 2021 | 642.00 |
| Sep 30, 2021 | 1,518.00 |